OverviewSuggest Edit

Nordic Nanovector, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics in hematology and oncology. Its lead clinical-stage product candidate is Betalutin, an antibody-radionuclide-conjugate, which is in Phase I/II clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. The Company has a collaboration agreement with AREVA Med and Paul Scherrer Institute to develop antibody-drug conjugates for treating leukaemias; and LegoChem Biosciences and Heidelberg Pharma to develop Antibody Radionuclide conjugates.

TypePublic
Founded2009
HQOslo, NO
Websitenordicnanovector.com

Latest Updates

Employees (est.) (Dec 2020)37(-15%)
Share Price (Jan 2021)KR15.2
Cybersecurity ratingAMore

Key People/Management at Nordic Nanovector

Jean-Pierre Bizzari

Jean-Pierre Bizzari

Director
Rainer Boehm

Rainer Boehm

Director
Marco Renoldi

Marco Renoldi

Chief Operating Officer
Joanna Horobin

Joanna Horobin

Director
Jostein Dahle

Jostein Dahle

Chief Scientific Officer
Karin Meyer

Karin Meyer

Director
Show more

Nordic Nanovector Office Locations

Nordic Nanovector has offices in Oslo, Zug and Shrewsbury
Oslo, NO (HQ)
168 Kjelsåsveien
Zug, CH
10 Grafenauweg
Shrewsbury, GB
1 Brassey Rd
Show all (3)

Nordic Nanovector Financials and Metrics

Nordic Nanovector Revenue

Market capitalization (8-Jan-2021)

1.1b

Closing stock price (8-Jan-2021)

15.2
Nordic Nanovector's current market capitalization is kr1.1 b.
Show all financial metrics

Nordic Nanovector Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Nordic Nanovector Online and Social Media Presence

Embed Graph

Nordic Nanovector News and Updates

Nordic Nanovector - Financial Calendar 2021

OSLO, Norway, Dec. 21, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) provides an update for its Financial Calendar for 2021. 18 February 2021 - Quarterly Report - Q4'2020 / FY'2020 15 April 2021 - Annual General Meeting 26 May 2021 - Quarterly Report - Q1'2021 27 August 2021 -...

Nordic Nanovector to Present at DNB's 11th Annual Nordic Healthcare Conference

OSLO, Norway, Dec. 7, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces that its Interim CEO, Dr Lars Nieba will present a corporate overview via live webcast at DNB's 11th Annual Nordic Healthcare Conference, taking place on 15 December 2020. Presentations details are as...

Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in Diffuse Large B Cell Lymphoma

OSLO, Norway, Dec. 1, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)...

Nordic Nanovector announces change of its Oslo Børs ticker symbol to 'NANOV'

OSLO, Norway, Nov. 30, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces that the Company's ticker symbol on the Oslo Børs will change from 'NANO' to 'NANOV' and will be effective as of the start of trading on 30 November 2020. The change of ticker follows Oslo Børs'...

Nordic Nanovector ASA: Results for the Third Quarter 2020

OSLO, Norway, Nov. 19, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2020. A live webcast presentation by Nordic Nanovector's management team will take place today in Oslo at 08.30 CET, see details below. A link to the webcast and the...

Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial

OSLA, Norway, Nov. 19, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it enrolled the final two patients into the second safety cohort of its Phase 1 Archer-1 (LYMRIT 37-07) trial investigating safety and preliminary efficacy of Betalutin® (177Lu lilotomab...
Show more

Nordic Nanovector Frequently Asked Questions

  • When was Nordic Nanovector founded?

    Nordic Nanovector was founded in 2009.

  • Who are Nordic Nanovector key executives?

    Nordic Nanovector's key executives are Jean-Pierre Bizzari, Rainer Boehm and Marco Renoldi.

  • How many employees does Nordic Nanovector have?

    Nordic Nanovector has 37 employees.

  • Who are Nordic Nanovector competitors?

    Competitors of Nordic Nanovector include Y-mAbs Therapeutics, Molecular Partners and Abliva.

  • Where is Nordic Nanovector headquarters?

    Nordic Nanovector headquarters is located at 168 Kjelsåsveien, Oslo.

  • Where are Nordic Nanovector offices?

    Nordic Nanovector has offices in Oslo, Zug and Shrewsbury.

  • How many offices does Nordic Nanovector have?

    Nordic Nanovector has 3 offices.